| Characteristics | Taxane | Vinflunine | IO | Gem/Platin | Total |
|---|---|---|---|---|---|
| No. of patients (%) | 20 28,6 | 40 57,1 | 9 12,9 | 1 1,4 | 70 |
| OS median ± SD1 (month) |
18,6 ± 3,0 | 12,3 ± 0,2 | 14,5 ± 4,0 | 14,7 ± 2,1 | |
| ECOG 0-1/2-3 (%) |
18/2 (90/10) | 33/7 (82,5/17,5) | 9/0 (100/0) | 1/0 (100/0) | 61/9 (87,1/12,9) |
| Age group 1/2 (%) | 14/6 (70/30) | 25/15 (62,5/37,5) | 5/4 (55,6/44,4) | 0/1 (0/100) |
44/26 (62,9/37,1) |
| Alive/deceased (%) | 12/8 (60/40) | 24/16 (60/40) | 5/4 (55,5/44,4) | 0/1 | 41/29 (58,6/41,4) |
| Received 3rd line (%) | 7 (35) | 14 (35) | 3 (33,3) | 0 (0) | 24 (34,3) |
| Metastatic Site | |||||
| LYM only (%) | 7 (35) | 7 (17,5) | 2 (22,2) | 0 | 16 |
| HEP (%) | 5 (25) | 11 (27,5) | 5 (55,5) | 0 | 21 |
| Visceral other than HEP (%) | 8 (40) | 22 (55) | 2 (22,2) | 1 | 33 |
| Best remission | |||||
| CR | 1 | 0 | 0 | 0 | 1 |
| PR | 3 | 3 | 0 | 0 | 6 |
| SD2 | 4 | 4 | 3 | 0 | 11 |
| PD | 4 | 23 | 5 | 0 | 32 |
| N/A | 8 | 10 | 2 | 1 | 20 |
| No. of adverse events, all grades (CTC 3-4) | |||||
| Hematological | 11 (6) | 12 (1) | 5 (0) | 1 (0) | 29 (7) |
| Nausea | 3 (0) | 8 (0) | 5 (2) | 1 (0) | 17 (0) |
| Vomiting | 1 (0) | 2 (0) | 1 (0) | 1 (0) | 5 (0) |
| Diarrhea | 1 (0) | 1 (0) | 3 (2) | 0 | 5 (2) |
| Pain | 5 (1) | 14 (3) | 3 (0) | 1 (0) | 23 (4) |
| PNP | 4 (0) | 1 (0) | 2 (0) | 0 | 7 (0) |
| Treatment discontinuation due to toxicity | 2 | 2 | 0 | 0 | 4 |